Evotec SE’s partner, Bayer AG, has decided to advance a further program from the endometriosis multi-target alliance into clinical Phase I development. Evotec will receive a €2 million milestone payment upon first dosing in the Phase I trial and may be eligible for further clinical and sales milestones as well as royalties based on future progress during clinical development and potential commercialization. The companies entered into their endometriosis multi-target discovery alliance in Oc...